{
    "nodes": [
        {
            "ix": "5-758_v1_0",
            "content": "Use of cidofovir in pediatric patients with adenovirus infection",
            "ntype": "article-title",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_1",
            "content": "Abstract",
            "ntype": "abstract",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_2",
            "content": "Background : Adenoviruses contribute to morbidity and mortality among immunocompromised pediatric patients including stem cell and solid organ transplant recipients. Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompromised patients despite concern of potential nephrotoxicity.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_3",
            "content": "Methods : We conducted a retrospective 5-year review at Boston Children\u2019s Hospital of 16 patients (mean age = 6.5 years) receiving 19 courses of CDV. During therapy all pertinent data elements were reviewed to characterize potential response to therapy and incidence of renal dysfunction.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_4",
            "content": "Results: Of the 19 CDV courses prescribed, 16 courses (84%) were in patients who had a positive blood ADV Polymerase chain reaction (PCR) alone or in combination with positive ADV PCR/ Direct Immunofluorescence Assay (DFA) at another site. Respiratory symptoms with or without pneumonia were the most common presentation (10/19, 53%). In the majority of blood positive courses (10/16, 63%), viral clearance was also accompanied by clinical response. This was not the case in four courses where patients expired despite viral clearance, including one in which death was directly attributable to adenovirus. There was reversible renal dysfunction observed during the use of CDV.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_5",
            "content": "Conclusions: CDV appeared safe and reasonably tolerated for treatment of ADV in this pediatric population and was associated with viral response and clinical improvement in the majority of patients but reversible renal dysfunction was a side effect. Further studies of the efficacy of CDV for immunocompromised children with ADV infection are warranted.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_6",
            "content": "Introduction",
            "ntype": "title",
            "meta": {
                "section": "1",
                "sec-type": "intro",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_7",
            "content": "Adenovirus (ADV) is a common cause of respiratory infection in childhood. ADV infections are usually self-limited and asymptomatic in the immunocompetent host but have been recognized as a cause of significant morbidity and mortality in immunocompromised pediatric patients such as recipients of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) <REF-1> . In these patients, ADV is an opportunistic pathogen that may lead to severe localized disease including pneumonia/pneumonitis, hepatitis, hemorrhagic cystitis or disseminated disease with multiorgan failure <REF-2> \u2013 <REF-4> . Case fatality rates in immunocompromised patients with ADV pneumonia have been reported to be as high as 60% <REF-5> . Currently, there is no FDA-labeled product available for treatment of ADV infection though several agents have been administered for this indication including ribavirin <REF-6> , <REF-7> , ganciclovir <REF-8> , vidarabine <REF-9> , <REF-10> , immune globulin <REF-11> and cidofovir <REF-12> \u2013 <REF-21> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_8",
            "content": "Cidofovir (CDV), a nucleoside and phosphonate analogue is a broad-spectrum antiviral agent that inhibits viral DNA polymerase and has broad activity in vitro against multiple viruses including all serotypes of ADV <REF-22> , <REF-23> . CDV has an FDA indication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Although this drug does not have an FDA indication for treating ADV, there is evidence of in vivo efficacy of CDV against ADV <REF-12> , <REF-14> . While CDV at a standard dose of 5mg/kg has been reported as primary therapy for treatment of ADV infection in pediatric and adult hematopoietic stem cell transplantation (HSCT) patients <REF-12> , <REF-21> , concern exists regarding potential nephrotoxicity. These associated adverse effects have limited the use of CDV for treatment of ADV infections in pediatric patients. To minimize potential toxicity of CDV, modified dosing regimens such as the use of 1 mg/kg three times have been utilized <REF-14> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_9",
            "content": "Limited information regarding safety and efficacy of CDV in pediatric patients prompted us to review prior published studies in the literature and conduct a retrospective review of our inpatient use of CDV at Boston Children\u2019s Hospital (BCH).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_10",
            "content": "Methods",
            "ntype": "title",
            "meta": {
                "section": "2",
                "sec-type": "methods",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_11",
            "content": "Following Institutional Review Board (IRB) approval (IRB-P00015576), a retrospective chart review was conducted for all hospitalized patients at Boston Children\u2019s Hospital (BCH), who were prescribed CDV for adenovirus infection from January 2006 through December 2010. The following data were collected: (1) demographic information, (2) underlying disease state, (3) type of transplant, (4) duration of cidofovir therapy, (6) serum creatinine (SCr) (baseline, peak during therapy, and level up to 2 weeks post last dose), (7) concomitant nephrotoxins prescribed (acyclovir, amikacin, cyclosporine, foscarnet, gentamicin, liposomal amphotericin B, tacrolimus, tobramycin, vancomycin, and intravenous contrast media), (8) sites of ADV detection by viral direct fluorescent antibody (DFA), nucleic acid test, and/or culture, (9) viral quantitative PCR surveillance in blood and other sites of infection (all specimens were tested at least weekly before, during and to two weeks post last dose of CDV to evaluate for changes in viral load with a minimum three serial values being obtained before, during and at end of therapy); (10) symptoms of infection, and clinical course including response to therapy, (11) concomitant reduction of immunosuppression and (12) mortality and cause(s) of mortality. All blood sample testing for adenovirus quantitative PCR in blood was performed at the Boston Children\u2019s Hospital Virology Laboratory using our laboratory developed test, the Argene adenovirus assay (bioMerieux, Cambridge, MA). The Argene adenovirus assay contains primers and probes selective for a 138 base pair (bp) sequence in the Hexon gene of the adenovirus. Using a 5\u2019 nuclease assay, viral DNA is detected using the primers and fluorescent probes from the Argene assay kit by means of real time PCR in a Cepheid SmartCycler (Cepheid, Sunnyvale, CA).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_12",
            "content": "Definitions",
            "ntype": "title",
            "meta": {
                "section": "2.1",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_13",
            "content": "As there is no accepted definition for ADV infection or disease, we adopted definitions used in prior studies <REF-13> . Specifically, definite adenovirus disease as follows: Non-gastrointestinal locations : Symptoms and signs from the appropriate organ combined with histopathological documentation of adenovirus and/or adenovirus detection by culture, antigen test, or nucleic acid test from biopsy specimens (liver or lung), BAL fluid, or cerebrospinal fluid and without another identifiable cause; Gastrointestinal location : Symptoms together with detection of adenovirus from biopsy material by culture, antigen test, or nucleic acid test.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_14",
            "content": "Probable adenovirus disease as follows: Gastrointestinal tract : Detection of adenovirus in stool by culture, antigen test, or nucleic acid test together with symptoms; Urinary tract : Symptoms of dysuria or hematuria combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause; and Respiratory tract: Symptoms and signs of pneumonia/pneumonitis combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_15",
            "content": "Asymptomatic adenovirus infection as follows: any detection of adenovirus in an asymptomatic patient from stool, blood, urine, or upper airway specimens by viral culture, antigen tests, or PCR.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_16",
            "content": "Adenoviremia was defined as the detection of >100 copies of ADV/mL of blood (this being the lower limit of detection of the assay). Viral clearance was defined as an ADV viral load of <100 copies in blood by quantitative PCR at the end of therapy. Viral response was defined as decrease in viremia by at least one log-fold. Clinical resolution was defined as resolution of symptoms and/or signs of infection. Renal dysfunction was defined as a \u226550% increase in SCr from baseline during the course of CDV therapy. The peak SCr during therapy was used to calculate the number of patients that experienced renal dysfunction.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_17",
            "content": "Statistical analysis",
            "ntype": "title",
            "meta": {
                "section": "2.2",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_18",
            "content": "Statistical analyses employed Prism 5 for Windows Version 5.04 (GraphPad Software Inc, CA). The Mann-Whitney test was used to assess risk of renal dysfunction. Trends in adenoviremia including pre-treatment viral load, changes in viral load during therapy, and post-treatment viral load were graphed.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_19",
            "content": "Results",
            "ntype": "title",
            "meta": {
                "section": "3",
                "sec-type": "results",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_20",
            "content": "<supplementary-material xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"DS0\" xlink:href=\"https://f1000researchdata.s3.amazonaws.com/datasets/8374/e8fe44e3-75e2-4790-8421-f1b56b703133_F1000_Viremia_raw_data_LG_csv.csv\"> <label>Raw data for Figure 1</label> <caption> <p>Adenovirus blood viral load is represented in each column at each particular time in days (before or after onset of cidofovir treatment) for each patient.</p> </caption> </supplementary-material>",
            "ntype": "supplementary-material",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_21",
            "content": "<supplementary-material xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"DS1\" xlink:href=\"https://f1000researchdata.s3.amazonaws.com/datasets/8374/5d083860-06be-43fa-af52-874c2d0ef5d9_F1000_Creatinine_raw_data_csv.csv\"> <label>Raw data for Figure 2</label> <caption> <p>Nephrotoxicity - pre, peak and post serum creatinine levels in mg/dL are represented in each column for each patient.</p> </caption> </supplementary-material>",
            "ntype": "supplementary-material",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_22",
            "content": "From January 1, 2006 to December 31, 2010, a total of 16 pediatric patients received CDV for adenovirus infection at our hospital. These 16 patients received 19 courses (three patients received two separate CDV courses). The standard CDV dose of 5mg/kg weekly was used in all courses unless there was concern for renal dysfunction at the start of therapy in which case a dosing regimen of 1mg/kg three times a week was used. Patient demographics, primary diagnosis, clinical symptoms and course, and sites of adenovirus detection appear in Table 1 . Patient age ranged from 0.75\u201320 years (mean 6.5 years). Seven (44%) patients were male. Underlying primary diagnosis included 8 (50%) HSCT (1 autologous), 4 (25%) SOT, 2 (12.5%) leukemia, and 2 (6.5%) defined as other. Duration of CDV therapy ranged from 5\u201382 days (median 33.5 days).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_23",
            "content": "Table 1.",
            "ntype": "label",
            "meta": {
                "id": "T1",
                "caption": "Demographics, primary diagnosis, sites of ADV detection, clinical symptoms and course of patients included in the study. The age and gender distribution, primary diagnosis, sites of adenovirus detection, symptoms and clinical course of the patients included in the study are shown.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_24",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T1\" position=\"anchor\"> <caption> <title>Demographics, primary diagnosis, sites of ADV detection, clinical symptoms and course of patients included in the study.</title> <p>The age and gender distribution, primary diagnosis, sites of adenovirus detection, symptoms and clinical course of the patients included in the study are shown.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\">Pt #</th> <th align=\"left\">Age <break/>(yrs)</th> <th align=\"left\">Gender</th> <th align=\"center\">Diagnosis</th> <th align=\"center\">Site(s) of ADV <break/>detection</th> <th align=\"center\">Clinical symptoms</th> </tr> </thead> <tbody> <tr> <td align=\"center\" valign=\"top\">1a</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">AML - Mismatched UD Cord SCT</td> <td align=\"center\" valign=\"top\">Sp, S, R</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">1b</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">AML - Mismatched UD Cord SCT</td> <td align=\"center\" valign=\"top\">Sp</td> <td align=\"center\" valign=\"top\">Fever and Respiratory symptoms</td> </tr> <tr> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Severe Idiosyncratic Immunodeficiency <break/>- MRD SCT</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Prolonged fever</td> </tr> <tr> <td align=\"center\" valign=\"top\">3</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">AML - Chemotherapy</td> <td align=\"center\" valign=\"top\">B, S, U</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Neuroblastoma - Autologous SCT</td> <td align=\"center\" valign=\"top\">B, S, PF</td> <td align=\"center\" valign=\"top\">Prolonged fever, pericardial effusion</td> </tr> <tr> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"top\">19</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Cystic Fibrosis - Lung Transplant</td> <td align=\"center\" valign=\"top\">B, BAL</td> <td align=\"center\" valign=\"top\">Asymptomatic</td> </tr> <tr> <td align=\"center\" valign=\"top\">*6</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Familial HLH - MUD SCT</td> <td align=\"center\" valign=\"top\">B, Sp</td> <td align=\"center\" valign=\"top\">Pneumonia, sepsis. Other <break/>co-infections including Enterococcus <break/>bacteremia, EBV viremia</td> </tr> <tr> <td align=\"center\" valign=\"top\">*7</td> <td align=\"center\" valign=\"top\">0.83</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Persistent pulmonary hypertension, <break/>cardiomyopathy</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Fever, sepsis, pneumonia. Other <break/>co-infections including <break/>stenotrophomonas bacteremia</td> </tr> <tr> <td align=\"center\" valign=\"top\">8a</td> <td align=\"center\" valign=\"top\">20</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">ALL - MRD SCT and MUD SCT</td> <td align=\"center\" valign=\"top\">BAL, B, U</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">8b</td> <td align=\"center\" valign=\"top\">20</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">ALL - MRD SCT and MUD SCT</td> <td align=\"center\" valign=\"top\">S</td> <td align=\"center\" valign=\"top\">Asymptomatic</td> </tr> <tr> <td align=\"center\" valign=\"top\">9</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Congenital Nephrotic Syndrome &amp; <break/>Hepatoblastoma - Combined Liver &amp; <break/>Kidney Transplant</td> <td align=\"center\" valign=\"top\">B,Sp</td> <td align=\"center\" valign=\"top\">Respiratory symptoms</td> </tr> <tr> <td align=\"center\" valign=\"top\">*10</td> <td align=\"center\" valign=\"top\">0.75</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">HLH - SCT</td> <td align=\"center\" valign=\"top\">S, B, U</td> <td align=\"center\" valign=\"top\">Fever, sepsis, diarrhea</td> </tr> <tr> <td align=\"center\" valign=\"top\">*11</td> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">CID and Lymphoproliferative Disorder <break/>- Mismatched UD Cord SCT</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Fever, respiratory symptoms, diarrhea, <break/>hemorrhagic cystitis</td> </tr> <tr> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Congenital Cardiac Defect - Heart <break/>Transplant</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Fever, sepsis</td> </tr> <tr> <td align=\"center\" valign=\"top\">13</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">ALL - Chemotherapy</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Fever, respiratory symptoms</td> </tr> <tr> <td align=\"center\" valign=\"top\">14</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Cerebral Palsy</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">15a</td> <td align=\"center\" valign=\"top\">1.8</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Hepatoblastoma - Multiviseral Transplant</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Increased stoma output, rejection, <break/>biopsy proven ADV In stoma mucosa</td> </tr> <tr> <td align=\"center\" valign=\"top\">15b</td> <td align=\"center\" valign=\"top\">1.8</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Hepatoblastoma - Multiviseral Transplant</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Increased stoma output</td> </tr> <tr> <td align=\"center\" valign=\"top\">*16</td> <td align=\"center\" valign=\"top\">17</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">AML - MUD SCT</td> <td align=\"center\" valign=\"top\">B, U</td> <td align=\"center\" valign=\"top\">Hemorrhagic cystitis. Other <break/>co-infections including BK viruria and <break/>EBV viremia</td> </tr> </tbody> </table> <table-wrap-foot> <fn> <p>ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CID, congenital immunodeficiency; CML, chronic myelogenous leukemia; HLH, hemophagocytic lymphohistiocytosis; MRD, matched related donor; MUD, matched unrelated donor; Pt #, patient number; SCID, severe combined immunodeficiency disorder; SCT, stem cell transplant; UD, unrelated donor; Yrs, years; Site of adenovirus detection: S, stool, Sp, sputum, B, blood, BAL, bronchoalveolar lavage, R, respiratory DFA, CSF, cerebrospinal fluid, U, Urine, PF, Pericardial Fluid; *indicates patient expired</p> </fn> </table-wrap-foot> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T1",
                "caption": "Demographics, primary diagnosis, sites of ADV detection, clinical symptoms and course of patients included in the study. The age and gender distribution, primary diagnosis, sites of adenovirus detection, symptoms and clinical course of the patients included in the study are shown.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_25",
            "content": "Of the 19 courses prescribed ( Table 1 ), two courses were prescribed in a patient with definite adenovirus disease of the gastrointestinal tract, 15 courses were prescribed in patients with probable disease and two courses were prescribed in patients with asymptomatic infection. Sixteen courses (84%) were in patients who had a positive blood ADV PCR either in whole blood only or in combination with positive ADV PCR of sputum, stool, urine, broncho-alveolar lavage (BAL) fluid, pericardial fluid or positive sputum adenoviral DFA sample. Respiratory symptoms were the most common presentation in 10 courses (53%) of which six courses were prescribed for patients with respiratory symptoms and radiological evidence of pneumonia. Two courses were prescribed in patients who presented with prolonged fevers; four courses were prescribed in patients who had worsening diarrhea and colitis, two of which were biopsy proven adenovirus infection; four courses were prescribed in patients with viral sepsis with or without pneumonia; and two courses were administered in patients with severe hemorrhagic cystitis. Two courses were prescribed in patients with asymptomatic respiratory tract infection and asymptomatic gastrointestinal infection respectively.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_26",
            "content": "We further examined the 16 blood-positive courses to assess trends in ADV viral load pre-, during and post- CDV therapy ( Figure 1 ). A quantitative reduction in viral load was seen in 15 blood positive courses (94%) with viral clearance achieved in 14 (88%). Of note, all solid organ transplant recipients treated with CDV also had concomitant decrease in their immunosuppression. A single patient (Patient 6) did not demonstrate viral response to therapy and expired. The majority of adenovirus blood-positive CDV courses (10/16, 63%) were associated with clinical improvement with viral clearance, however this was not the case in four courses. Patients 7, 10, 11 and 16 expired despite demonstrating viral clearance. Patients 6, 7 and 16 had multiple other co-infections. Patients 11 and 16 developed severe hemorrhagic cystitis. Patient 11 experienced significant complications of hemorrhagic cystitis including urinary tract obstruction, renal failure and bladder perforation. Patient 16 also had concomitant BK Polyoma virus detected in the urine.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_27",
            "content": "Figure 1.",
            "ntype": "label",
            "meta": {
                "id": "f1",
                "caption": "Kinetics of Adenovirus blood viral load under cidofovir treatment. Viral loads of 16 patients with quantitative blood adenovirus PCR treated with cidofovir, are shown. Day of therapy \u22640 denotes pre-treatment viral loads. Up to two post-treatment values are shown where available and informative. Each patient\u2019s individual treatment duration is shown in the legend. + denotes patient expired.",
                "uri": "https://f1000researchdata.s3.amazonaws.com/manuscripts/9007/d15fd449-79a1-49c1-aabd-e4c3ea3b4a92_figure1.gif",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_28",
            "content": "<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" fig-type=\"figure\" id=\"f1\" position=\"float\"> <caption> <title>Kinetics of Adenovirus blood viral load under cidofovir treatment.</title> <p>Viral loads of 16 patients with quantitative blood adenovirus PCR treated with cidofovir, are shown. Day of therapy &#8804;0 denotes pre-treatment viral loads. Up to two post-treatment values are shown where available and informative. Each patient&#8217;s individual treatment duration is shown in the legend. <bold>+</bold> denotes patient expired.</p> </caption> <graphic xlink:href=\"https://f1000researchdata.s3.amazonaws.com/manuscripts/9007/d15fd449-79a1-49c1-aabd-e4c3ea3b4a92_figure1.gif\"/> </fig>",
            "ntype": "fig",
            "meta": {
                "id": "f1",
                "caption": "Kinetics of Adenovirus blood viral load under cidofovir treatment. Viral loads of 16 patients with quantitative blood adenovirus PCR treated with cidofovir, are shown. Day of therapy \u22640 denotes pre-treatment viral loads. Up to two post-treatment values are shown where available and informative. Each patient\u2019s individual treatment duration is shown in the legend. + denotes patient expired.",
                "uri": "https://f1000researchdata.s3.amazonaws.com/manuscripts/9007/d15fd449-79a1-49c1-aabd-e4c3ea3b4a92_figure1.gif",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_29",
            "content": "Each patient\u2019s medication profile was assessed to determine the number of additional nephrotoxic agents concomitantly prescribed during CDV therapy (from Day 1 to 7 days post last CDV dose). All 19 courses prescribed had at least one additional nephrotoxic agent prescribed during CDV therapy ( Table 2 ). Four courses (21%) had only one additional nephrotoxic medication prescribed, five courses (26%) had two such medications prescribed, six courses (32%) had three prescribed, two courses (11%) had four prescribed, and two courses (11%) had five prescribed.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_30",
            "content": "Table 2.",
            "ntype": "label",
            "meta": {
                "id": "T2",
                "caption": "Additional nephrotoxic agents prescribed and changes in serum creatinine during cidofovir therapy. Absolute values for serum creatinine in mg/dL for each patient are represented pre-treatment, during treatment (peak serum creatinine), and post-treatment. Additional nephrotoxic agents that each patient received are also represented.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_31",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T2\" position=\"anchor\"> <caption> <title>Additional nephrotoxic agents prescribed and changes in serum creatinine during cidofovir therapy.</title> <p>Absolute values for serum creatinine in mg/dL for each patient are represented pre-treatment, during treatment (peak serum creatinine), and post-treatment. Additional nephrotoxic agents that each patient received are also represented.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\" valign=\"top\">Pt #</th> <th align=\"center\" valign=\"top\">Pre-treatment <break/>Serum Cr</th> <th align=\"center\" valign=\"top\">Peak <break/>Serum <break/>Cr</th> <th align=\"center\" valign=\"top\">Post-treatment <break/>Serum Cr</th> <th align=\"center\" valign=\"top\">Additional nephrotoxic agents</th> </tr> </thead> <tbody> <tr> <td align=\"center\" valign=\"top\">1a</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">1.2</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">ambisome, cyclosporine, gentamicin</td> </tr> <tr> <td align=\"center\" valign=\"top\">1b</td> <td align=\"center\" valign=\"top\">0.6</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">0.6</td> <td align=\"center\" valign=\"top\">cyclosporine</td> </tr> <tr> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"bottom\">0.5</td> <td align=\"center\" valign=\"top\">cyclosporine, ganciclovir, pentamidine</td> </tr> <tr> <td align=\"center\" valign=\"top\">3</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">0.6</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">vancomycin, ambisome, gentamicin</td> </tr> <tr> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">acyclovir</td> </tr> <tr> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"top\">0.4</td> <td align=\"center\" valign=\"top\">0.7</td> <td align=\"center\" valign=\"top\">0.5</td> <td align=\"center\" valign=\"top\">tacrolimus</td> </tr> <tr> <td align=\"center\" valign=\"top\">6</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.4</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">ambisome, ganciclovir, pentamidine, tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">7</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">0.5</td> <td align=\"center\" valign=\"top\">0.7</td> <td align=\"center\" valign=\"top\">gentamicin, tobramycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">8a</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">1.7</td> <td align=\"center\" valign=\"top\">0.4</td> <td align=\"center\" valign=\"top\">ambisome, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">8b</td> <td align=\"center\" valign=\"top\">0.4</td> <td align=\"center\" valign=\"top\">2.6</td> <td align=\"center\" valign=\"top\">1.3</td> <td align=\"center\" valign=\"top\">ganciclovir, tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">9</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">2.7</td> <td align=\"center\" valign=\"top\">0.6</td> <td align=\"center\" valign=\"top\">chemotherapy</td> </tr> <tr> <td align=\"center\" valign=\"top\">10</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"top\">acyclovir, ambisome, cyclosporine, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">11</td> <td align=\"center\" valign=\"bottom\">0.4</td> <td align=\"center\" valign=\"bottom\">1.6</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">gentamicin, acyclovir, ambisome, cyclosporine, foscarnet, ganciclovir</td> </tr> <tr> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">0.5</td> <td align=\"center\" valign=\"top\">1.6</td> <td align=\"center\" valign=\"top\">0.6</td> <td align=\"center\" valign=\"top\">gentamicin, ganciclovir, tacrolimus</td> </tr> <tr> <td align=\"center\" valign=\"top\">13</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">ambisome,foscarnet,ganciclovir</td> </tr> <tr> <td align=\"center\" valign=\"top\">14</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">15a</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">15b</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">0.3</td> <td align=\"center\" valign=\"top\">0.2</td> <td align=\"center\" valign=\"top\">tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">16</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.5</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"top\">cyclosporine, gentamicin, vancomycin, contrast</td> </tr> </tbody> </table> <table-wrap-foot> <fn> <p>Pt #, patient number; Cr, creatinine; all creatinine values are in mg/dL.</p> </fn> </table-wrap-foot> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T2",
                "caption": "Additional nephrotoxic agents prescribed and changes in serum creatinine during cidofovir therapy. Absolute values for serum creatinine in mg/dL for each patient are represented pre-treatment, during treatment (peak serum creatinine), and post-treatment. Additional nephrotoxic agents that each patient received are also represented.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_32",
            "content": "Administration of CDV was significantly associated with occurrence of renal dysfunction when comparing the peak Cr measured during CDV therapy to the baseline serum Cr (p=0.0016). Eleven courses (58%) were associated with development of renal dysfunction. Cr increased by a mean of ~50% from baseline during CDV therapy ( Figure 2 ). Of the courses with elevation in serum creatinine, 64% demonstrated return to pre-treatment creatinine levels following cessation of CDV therapy. There was no statistically significant difference when assessing for increased risk of renal dysfunction if patients received \u2264 1 additional nephrotoxic agent or \u2265 2 additional nephrotoxic agents.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_33",
            "content": "Figure 2.",
            "ntype": "label",
            "meta": {
                "id": "f2",
                "caption": "Change in serum creatinine during, and at the end of cidofovir therapy compared to pre-treatment serum creatinine. The y axis represents change in serum creatinine (in percentage) compared to pre-treatment serum creatinine. During therapy, serum creatinine increased by a mean of 50%. *** indicates p<0.01; NS indicates change is not significant.",
                "uri": "https://f1000researchdata.s3.amazonaws.com/manuscripts/9007/d15fd449-79a1-49c1-aabd-e4c3ea3b4a92_figure2.gif",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_34",
            "content": "<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" fig-type=\"figure\" id=\"f2\" position=\"float\"> <caption> <title>Change in serum creatinine during, and at the end of cidofovir therapy compared to pre-treatment serum creatinine.</title> <p>The y axis represents change in serum creatinine (in percentage) compared to pre-treatment serum creatinine. During therapy, serum creatinine increased by a mean of 50%. *** indicates p&lt;0.01; NS indicates change is not significant.</p> </caption> <graphic xlink:href=\"https://f1000researchdata.s3.amazonaws.com/manuscripts/9007/d15fd449-79a1-49c1-aabd-e4c3ea3b4a92_figure2.gif\"/> </fig>",
            "ntype": "fig",
            "meta": {
                "id": "f2",
                "caption": "Change in serum creatinine during, and at the end of cidofovir therapy compared to pre-treatment serum creatinine. The y axis represents change in serum creatinine (in percentage) compared to pre-treatment serum creatinine. During therapy, serum creatinine increased by a mean of 50%. *** indicates p<0.01; NS indicates change is not significant.",
                "uri": "https://f1000researchdata.s3.amazonaws.com/manuscripts/9007/d15fd449-79a1-49c1-aabd-e4c3ea3b4a92_figure2.gif",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_35",
            "content": "Discussion",
            "ntype": "title",
            "meta": {
                "section": "4",
                "sec-type": "discussion",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_36",
            "content": "In this retrospective review of patients treated with CDV for adenovirus infection at our hospital during a 5-year period, we assessed the safety and potential efficacy of the medication in pediatric patients. Our review yielded a case series of 16 patients. While the number of patients is modest, this series adds to the existing literature describing the use of CDV in pediatric recipients of HSCT, SOT and chemotherapy for oncologic diagnoses ( Table 3 ).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_37",
            "content": "Table 3.",
            "ntype": "label",
            "meta": {
                "id": "T3",
                "caption": "Summary of studies describing use of cidofovir in pediatric HSCT and SOT recipient. Published studies in the literature describing use of cidofovir in pediatric HSCT and SOT recipients are summarized. Toxicities, and clinical outcomes reported in each study are highlighted.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_38",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T3\" position=\"anchor\"> <caption> <title>Summary of studies describing use of cidofovir in pediatric HSCT and SOT recipient.</title> <p>Published studies in the literature describing use of cidofovir in pediatric HSCT and SOT recipients are summarized. Toxicities, and clinical outcomes reported in each study are highlighted.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\" valign=\"top\">Study</th> <th align=\"center\" valign=\"top\"># Patients <break/>(N)</th> <th align=\"center\" valign=\"top\">Clinical <break/>Setting</th> <th align=\"center\" valign=\"top\">Median <break/>Age</th> <th align=\"left\" valign=\"top\">Cidofovir dosage</th> <th align=\"left\" valign=\"top\">Duration <break/>of <break/>cidofovir <break/>use</th> <th align=\"left\" valign=\"top\">Potential <break/>Toxicity</th> <th align=\"left\" valign=\"top\">Outcome</th> </tr> </thead> <tbody> <tr> <td align=\"center\" valign=\"top\">Hoffman <sup> <xref ref-type=\"bibr\" rid=\"ref-14\">14</xref> </sup> </td> <td align=\"center\" valign=\"top\">8</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">7 yrs</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose three <break/>times weekly &#215; 9 doses <break/>or until clearance</td> <td align=\"left\" valign=\"top\">3 weeks&#8211;8 <break/>months</td> <td align=\"left\" valign=\"top\">Well tolerated; <break/>no toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">100% viral suppression <break/>3 recurrences <break/>4 expired (2 ADV- <break/>related)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Muller <sup> <xref ref-type=\"bibr\" rid=\"ref-12\">12</xref> </sup> </td> <td align=\"center\" valign=\"top\">10</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">Not <break/>reported</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose weekly <break/>up to 6 weeks, then <break/>every other week for 3 <break/>more doses</td> <td align=\"left\" valign=\"top\">3 weeks&#8211;6 <break/>months</td> <td align=\"left\" valign=\"top\">30% <break/>nephrotoxicity <break/>(50% increase <break/>Cr)</td> <td align=\"left\" valign=\"top\">9 virologic <break/>clearance <break/>5 recurrences <break/>1 expired (interstitial <break/>pneumonitis)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Anderson <sup> <xref ref-type=\"bibr\" rid=\"ref-19\">19</xref> </sup> </td> <td align=\"center\" valign=\"top\">7</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">1.5 yrs</td> <td align=\"left\" valign=\"top\">Preemptive therapy: <break/>1 mg/kg/dose three <break/>times weekly &#215; 3 weeks</td> <td align=\"left\" valign=\"top\">3 weeks</td> <td align=\"left\" valign=\"top\">Well tolerated <break/>without <break/>significant <break/>toxicity reported</td> <td align=\"left\" valign=\"top\">No patient developed <break/>ADV viremia <break/>2 expired (non-ADV <break/>related)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Bhadri <sup> <xref ref-type=\"bibr\" rid=\"ref-15\">15</xref> </sup> </td> <td align=\"center\" valign=\"top\">23</td> <td align=\"center\" valign=\"top\">87% HSCT <break/>13% oncologic <break/>receiving <break/>chemotherapy</td> <td align=\"center\" valign=\"top\">5.7 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose weekly, <break/>3 mg/kg/dose weekly <break/>or 1 mg/kg/dose three <break/>times weekly</td> <td align=\"left\" valign=\"top\">Median <break/>6 weeks <break/>(1&#8211;26 <break/>weeks)</td> <td align=\"left\" valign=\"top\">9% Grade 1 <break/>nephrotoxicity <break/>defined by <break/>increase of <break/>creatinine up to <break/>1.5 times upper <break/>limit of normal</td> <td align=\"left\" valign=\"top\">85% of 20 evaluable <break/>patients considered <break/>successful by <break/>Ljungman criteria <sup> <xref ref-type=\"bibr\" rid=\"ref-13\">13</xref> </sup> <break/>17 expired</td> </tr> <tr> <td align=\"center\" valign=\"top\">Yusuf <sup> <xref ref-type=\"bibr\" rid=\"ref-17\">17</xref> </sup> </td> <td align=\"center\" valign=\"top\">57</td> <td align=\"center\" valign=\"top\">90% HSCT <break/>10% oncologic <break/>receiving <break/>chemotherapy</td> <td align=\"center\" valign=\"top\">8 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose weekly <break/>&#215; 2 weeks, then every <break/>other week until 3 <break/>negative ADV samples</td> <td align=\"left\" valign=\"top\">Median <break/>60 days <break/>(1 week&#8211;9 <break/>months)</td> <td align=\"left\" valign=\"top\">No toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">98% successful viral <break/>clearance <break/>14% recurrence <break/>29 expired (1 ADV- <break/>related death)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Legrand <sup> <xref ref-type=\"bibr\" rid=\"ref-18\">18</xref> </sup> </td> <td align=\"center\" valign=\"top\">7</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">6.4 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose weekly <break/>&#215; 3 wks then every <break/>other wk or 10 days</td> <td align=\"left\" valign=\"top\">25&#8211;330 <break/>days</td> <td align=\"left\" valign=\"top\">43% <break/>nephrotoxicity</td> <td align=\"left\" valign=\"top\">71% deemed <break/>recovered <break/>2 expired (1 ADV <break/>related death)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Sivaprakasam <sup> <xref ref-type=\"bibr\" rid=\"ref-26\">26</xref> </sup> </td> <td align=\"center\" valign=\"top\">8</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">11 yrs</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose 3 times <break/>weekly (4 patients also <break/>received IV ribavirin <break/>5 mg/kg 3 times daily)</td> <td align=\"left\" valign=\"top\">Not <break/>reported</td> <td align=\"left\" valign=\"top\">2 cases marrow <break/>failure, 1 case <break/>nephropathy</td> <td align=\"left\" valign=\"top\">3 expired (attributed <break/>to ADV and GVHD)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Williams <sup> <xref ref-type=\"bibr\" rid=\"ref-27\">27</xref> </sup> </td> <td align=\"center\" valign=\"top\">9</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">3 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose once <break/>weekly until 3 weeks <break/>of negative results or <break/>pt no longer high risk; <break/>if underlying renal <break/>dysfunction 1 mg/kg/ <break/>dose 3 times weekly</td> <td align=\"left\" valign=\"top\">Median <break/>8 doses <break/>(3&#8211;32 <break/>doses)</td> <td align=\"left\" valign=\"top\">22% renal failure <break/>(compared to <break/>80% untreated <break/>comparator <break/>group)</td> <td align=\"left\" valign=\"top\">89% ADV clearance <break/>3 expired (1 ADV <break/>related)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Engelmann <sup> <xref ref-type=\"bibr\" rid=\"ref-16\">16</xref> </sup> </td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">Liver transplant</td> <td align=\"center\" valign=\"top\">7 months</td> <td align=\"left\" valign=\"top\">6 mg/kg/dose &#215; 1 with <break/>1 repeat dose 6 days <break/>later</td> <td align=\"left\" valign=\"top\">2 weeks</td> <td align=\"left\" valign=\"top\">No toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">Liver rejection; <break/>reported to have <break/>slow recovery</td> </tr> <tr> <td align=\"center\" valign=\"top\">Wallot <sup> <xref ref-type=\"bibr\" rid=\"ref-20\">20</xref> </sup> </td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">Liver transplant</td> <td align=\"center\" valign=\"top\">8 months <break/>and 14 <break/>months</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose three <break/>times weekly</td> <td align=\"left\" valign=\"top\">5&#8211;8 weeks</td> <td align=\"left\" valign=\"top\">1 moderate <break/>neutropenia, 1 <break/>transient rise in <break/>creatinine</td> <td align=\"left\" valign=\"top\">Blood PCR ADV <break/>clearance in both <break/>patients <break/>No deaths</td> </tr> <tr> <td align=\"center\" valign=\"top\">Carter <sup> <xref ref-type=\"bibr\" rid=\"ref-24\">24</xref> </sup> </td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">Liver transplant</td> <td align=\"center\" valign=\"top\">7 months</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose three <break/>times weekly</td> <td align=\"left\" valign=\"top\">7 weeks</td> <td align=\"left\" valign=\"top\">Transient <break/>acidosis and <break/>proteinuria</td> <td align=\"left\" valign=\"top\">ADV viral culture <break/>and blood PCR <break/>became negative</td> </tr> <tr> <td align=\"center\" valign=\"top\">Doan <sup> <xref ref-type=\"bibr\" rid=\"ref-25\">25</xref> </sup> </td> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">Lung transplant</td> <td align=\"center\" valign=\"top\">&lt;3 yrs</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose every <break/>other day to three <break/>times weekly plus IVIG <break/>(1 pt increased dose <break/>to 2 mg/kg/dose; <break/>1 pt increased <break/>frequency to daily <break/>therapy &#215; 2 weeks)</td> <td align=\"left\" valign=\"top\">4 weeks</td> <td align=\"left\" valign=\"top\">No toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">75% negative blood <break/>ADV PCR <break/>1 death</td> </tr> </tbody> </table> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T3",
                "caption": "Summary of studies describing use of cidofovir in pediatric HSCT and SOT recipient. Published studies in the literature describing use of cidofovir in pediatric HSCT and SOT recipients are summarized. Toxicities, and clinical outcomes reported in each study are highlighted.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_39",
            "content": "Similar to other studies the majority of our patients had received a HSCT or had an oncologic diagnosis and received chemotherapy. We identified eight publications describing the use of CDV for adenovirus infection in the setting of HSCT or oncologic diagnoses treated with chemotherapy ( Table 3 ). Three of these studies <REF-14> , <REF-17> , <REF-27> reported viral clearance in 89\u2013100% of their patients. We observed similar rates of viral clearance (88%) but this was not consistently associated with clinical improvement.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_40",
            "content": "There are very few reports on the use of CDV for adenovirus infection in pediatric SOT recipients, which have largely been restricted to reports of children receiving liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> . We identified four publications reporting the use of CDV for adenovirus infection in pediatric SOT recipients limited to one to four per report and all of these children having received liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> . Doan et al. <REF-25> described children who had received lung transplants with reported viral clearance in three of their four patients. Our case series contributes patients who received several types of SOT including lung, heart, combined kidney and liver, and multi-visceral transplants. All patients with SOT in our series demonstrated viral clearance as well as resolution of symptoms, which may have reflected a combination of both the antiviral effect of CDV coupled with reduced immunosuppression.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_41",
            "content": "Two-thirds of our patients experienced resolution of their symptoms and had an overall favorable clinical course with recovery. However, one-third died all of which were stem cell transplant recipients. With the exception of one patient it is unclear whether adenovirus was the direct cause of mortality in these patients. Our observations are consistent with what has been reported in the literature pertaining to outcomes in stem cell transplant recipients with adenovirus infections who have been treated with CDV <REF-9> , <REF-12> , <REF-14> , <REF-18> , <REF-23> , <REF-27> . Among SCT patients mortality remains high (10%\u201370%) even when clearance from blood is seen.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_42",
            "content": "In our case series, renal dysfunction was common during CDV therapy with patients experiencing an average 50% increase of serum creatinine from their baseline. However, renal dysfunction was transient in the majority of patients with serum creatinine returning to baseline after cessation of CDV therapy. While some studies have reported no toxicities related to the use of CDV <REF-14> , <REF-16> , <REF-17> , <REF-19> , <REF-25> , the transient nature of nephrotoxicity observed has been reported by other studies <REF-20> , <REF-24> . We were unable to detect any increased risk of nephrotoxicity associated with concomitant administration of additional nephrotoxic agents but this may reflect our small number of study participants.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_43",
            "content": "Our study has several limitations. Most notably, the small number of patients precluded evaluation of other factors that may impact infection resolution such as immunosuppressive regimens, and additional factors that may impact degree of renal dysfunction. Nevertheless, our study adds to the limited reported literature of pediatric ADV patients treated with CDV.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_44",
            "content": "Data availability",
            "ntype": "title",
            "meta": {
                "section": "5",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_45",
            "content": "The data referenced by this article are under copyright with the following copyright statement: Copyright: \u00ef\u00bf\u00bd 2016 Ganapathi L et al.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_46",
            "content": "Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_47",
            "content": "F1000Research : Dataset 1. Raw data for Figure 1 , 10.5256/f1000research.8374.d117321 <REF-28>",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_48",
            "content": "F1000Research : Dataset 2. Raw data for Figure 2 , 10.5256/f1000research.8374.d117322 <REF-29>",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_49",
            "content": "<REF-1> Ison MG : Adenovirus infections in transplant recipients. Clin Infect Dis. 2006 ; 43 ( 3 ): 331 \u2013 339 . 16804849 10.1086/505498",
            "ntype": "ref",
            "meta": {
                "id": "ref-1",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_50",
            "content": "<REF-2> Carrigan DR : Adenovirus infections in immunocompromised patients. Am J Med. 1997 ; 102 ( 3A ): 71 \u2013 74 . 10868146",
            "ntype": "ref",
            "meta": {
                "id": "ref-2",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_51",
            "content": "<REF-4> Hale GA Heslop HE Krance RA : Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 ; 23 ( 3 ): 277 \u2013 282 . 10084260",
            "ntype": "ref",
            "meta": {
                "id": "ref-4",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_52",
            "content": "<REF-5> Hierholzer JC : Adenoviruses in the immunocompromised host. Clin Microbiol Rev. 1992 ; 5 ( 3 ): 262 \u2013 274 . 1323383 358244",
            "ntype": "ref",
            "meta": {
                "id": "ref-5",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_53",
            "content": "<REF-6> Gavin PJ Katz BZ : Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics. 2002 ; 110 ( 1 Pt 1 ): e9 . 12093990",
            "ntype": "ref",
            "meta": {
                "id": "ref-6",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_54",
            "content": "<REF-7> McCarthy AJ Bergin M De Silva LM : Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J. 1995 ; 14 ( 11 ): 1003 \u2013 1004 . 8584339 10.1097/00006454-199511000-00017",
            "ntype": "ref",
            "meta": {
                "id": "ref-7",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_55",
            "content": "<REF-8> Chen FE Liang RH Lo JY : Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 1997 ; 20 ( 11 ): 997 \u2013 999 . 9422482 10.1038/sj.bmt.1700997",
            "ntype": "ref",
            "meta": {
                "id": "ref-8",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_56",
            "content": "<REF-9> Kawakami M Ueda S Maeda T : Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997 ; 20 ( 6 ): 485 \u2013 490 . 9313882 10.1038/sj.bmt.1700923",
            "ntype": "ref",
            "meta": {
                "id": "ref-9",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_57",
            "content": "<REF-10> Kitabayashi A Hirokawa M Kuroki J : Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 ; 14 ( 5 ): 853 \u2013 854 . 7889020",
            "ntype": "ref",
            "meta": {
                "id": "ref-10",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_58",
            "content": "<REF-11> Saquib R Melton LB Chandrakantan A : Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis. 2010 ; 12 ( 1 ): 77 \u2013 83 . 19761559 10.1111/j.1399-3062.2009.00452.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-11",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_59",
            "content": "<REF-12> Muller WJ Levin MJ Shin YK : Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 2005 ; 41 ( 12 ): 1812 \u2013 1816 . 16288409 10.1086/498151",
            "ntype": "ref",
            "meta": {
                "id": "ref-12",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_60",
            "content": "<REF-13> Ljungman P Ribaud P Eyrich M : Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2003 ; 31 ( 6 ): 481 \u2013 486 . 12665844 10.1038/sj.bmt.1703798",
            "ntype": "ref",
            "meta": {
                "id": "ref-13",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_61",
            "content": "<REF-14> Hoffman JA Shah AJ Ross LA : Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001 ; 7 ( 7 ): 388 \u2013 394 . 11529489 10.1053/bbmt.2001.v7.pm11529489",
            "ntype": "ref",
            "meta": {
                "id": "ref-14",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_62",
            "content": "<REF-16> Engelmann G Heim A Greil J : Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr Transplant. 2009 ; 13 ( 4 ): 421 \u2013 428 . 18783361 10.1111/j.1399-3046.2008.01014.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-16",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_63",
            "content": "<REF-17> Yusuf U Hale GA Carr J : Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006 ; 81 ( 10 ): 1398 \u2013 1404 . 16732176 10.1097/01.tp.0000209195.95115.8e",
            "ntype": "ref",
            "meta": {
                "id": "ref-17",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_64",
            "content": "<REF-18> Legrand F Berrebi D Houhou N : Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 2001 ; 27 ( 6 ): 621 \u2013 626 . 11319592",
            "ntype": "ref",
            "meta": {
                "id": "ref-18",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_65",
            "content": "<REF-19> Anderson EJ Guzman-Cottrill JA Kletzel M : High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant. 2008 ; 12 ( 2 ): 219 \u2013 227 . 18307672 10.1111/j.1399-3046.2007.00851.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-19",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_66",
            "content": "<REF-20> Wallot MA Dohna-Schwake C Auth M : Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide. Pediatr Transplant. 2006 ; 10 ( 1 ): 121 \u2013 127 . 16499602 10.1111/j.1399-3046.2005.00411.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-20",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_67",
            "content": "<REF-21> Ribaud P Scieux C Freymuth F : Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis. 1999 ; 28 ( 3 ): 690 \u2013 691 . 10194105 10.1086/517222",
            "ntype": "ref",
            "meta": {
                "id": "ref-21",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_68",
            "content": "<REF-22> Naesens L Lenaerts L Andrei G : Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother. 2005 ; 49 ( 3 ): 1010 \u2013 1016 . 15728896 10.1128/AAC.49.3.1010-1016.2005 549266",
            "ntype": "ref",
            "meta": {
                "id": "ref-22",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_69",
            "content": "<REF-23> Morfin F Dupuis-Girod S Mundweiler S : In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther. 2005 ; 10 ( 2 ): 225 \u2013 229 . 15865216",
            "ntype": "ref",
            "meta": {
                "id": "ref-23",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_70",
            "content": "<REF-24> Carter BA Karpen SJ Quiros-Tejeira RE : Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 ; 74 ( 7 ): 1050 \u2013 1052 . 12394854",
            "ntype": "ref",
            "meta": {
                "id": "ref-24",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_71",
            "content": "<REF-25> Doan ML Mallory GB Kaplan SL : Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant. 2007 ; 26 ( 9 ): 883 \u2013 889 . 17845926 10.1016/j.healun.2007.06.009",
            "ntype": "ref",
            "meta": {
                "id": "ref-25",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_72",
            "content": "<REF-27> Williams KM Agwu AL Dabb AA : A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection. J Pediatr Hematol Oncol. 2009 ; 31 ( 11 ): 825 \u2013 831 . 19801951 10.1097/MPH.0b013e3181b7873e 4251427",
            "ntype": "ref",
            "meta": {
                "id": "ref-27",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_73",
            "content": "<REF-28> Ganapathi L Arnold A Jones S : Dataset 1 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "ref",
            "meta": {
                "id": "ref-28",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v1_74",
            "content": "<REF-29> Ganapathi L Arnold A Jones S : Dataset 2 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "ref",
            "meta": {
                "id": "ref-29",
                "created_by": "F1000XMLParser"
            }
        }
    ],
    "span_nodes": [
        {
            "ix": "5-758_v1_0@0",
            "content": "Use of cidofovir in pediatric patients with adenovirus infection",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_0",
            "start": 0,
            "end": 63,
            "label": {}
        },
        {
            "ix": "5-758_v1_1@0",
            "content": "Abstract",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_1",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v1_2@0",
            "content": "Background : Adenoviruses contribute to morbidity and mortality among immunocompromised pediatric patients including stem cell and solid organ transplant recipients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_2",
            "start": 0,
            "end": 164,
            "label": {}
        },
        {
            "ix": "5-758_v1_2@1",
            "content": "Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompromised patients despite concern of potential nephrotoxicity.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_2",
            "start": 166,
            "end": 360,
            "label": {}
        },
        {
            "ix": "5-758_v1_3@0",
            "content": "Methods : We conducted a retrospective 5-year review at Boston Children\u2019s Hospital of 16 patients (mean age = 6.5 years) receiving 19 courses of CDV.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_3",
            "start": 0,
            "end": 148,
            "label": {}
        },
        {
            "ix": "5-758_v1_3@1",
            "content": "During therapy all pertinent data elements were reviewed to characterize potential response to therapy and incidence of renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_3",
            "start": 150,
            "end": 287,
            "label": {}
        },
        {
            "ix": "5-758_v1_4@0",
            "content": "Results: Of the 19 CDV courses prescribed, 16 courses (84%) were in patients who had a positive blood ADV Polymerase chain reaction (PCR) alone or in combination with positive ADV PCR/ Direct Immunofluorescence Assay (DFA) at another site.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_4",
            "start": 0,
            "end": 238,
            "label": {}
        },
        {
            "ix": "5-758_v1_4@1",
            "content": "Respiratory symptoms with or without pneumonia were the most common presentation (10/19, 53%).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_4",
            "start": 240,
            "end": 333,
            "label": {}
        },
        {
            "ix": "5-758_v1_4@2",
            "content": "In the majority of blood positive courses (10/16, 63%), viral clearance was also accompanied by clinical response.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_4",
            "start": 335,
            "end": 448,
            "label": {}
        },
        {
            "ix": "5-758_v1_4@3",
            "content": "This was not the case in four courses where patients expired despite viral clearance, including one in which death was directly attributable to adenovirus.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_4",
            "start": 450,
            "end": 604,
            "label": {}
        },
        {
            "ix": "5-758_v1_4@4",
            "content": "There was reversible renal dysfunction observed during the use of CDV.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_4",
            "start": 606,
            "end": 675,
            "label": {}
        },
        {
            "ix": "5-758_v1_5@0",
            "content": "Conclusions: CDV appeared safe and reasonably tolerated for treatment of ADV in this pediatric population and was associated with viral response and clinical improvement in the majority of patients but reversible renal dysfunction was a side effect.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_5",
            "start": 0,
            "end": 248,
            "label": {}
        },
        {
            "ix": "5-758_v1_5@1",
            "content": "Further studies of the efficacy of CDV for immunocompromised children with ADV infection are warranted.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_5",
            "start": 250,
            "end": 352,
            "label": {}
        },
        {
            "ix": "5-758_v1_6@0",
            "content": "Introduction",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_6",
            "start": 0,
            "end": 11,
            "label": {}
        },
        {
            "ix": "5-758_v1_7@0",
            "content": "Adenovirus (ADV) is a common cause of respiratory infection in childhood.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_7",
            "start": 0,
            "end": 72,
            "label": {}
        },
        {
            "ix": "5-758_v1_7@1",
            "content": "ADV infections are usually self-limited and asymptomatic in the immunocompetent host but have been recognized as a cause of significant morbidity and mortality in immunocompromised pediatric patients such as recipients of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) <REF-1> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_7",
            "start": 74,
            "end": 379,
            "label": {}
        },
        {
            "ix": "5-758_v1_7@2",
            "content": "In these patients, ADV is an opportunistic pathogen that may lead to severe localized disease including pneumonia/pneumonitis, hepatitis, hemorrhagic cystitis or disseminated disease with multiorgan failure <REF-2> \u2013 <REF-4> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_7",
            "start": 381,
            "end": 606,
            "label": {}
        },
        {
            "ix": "5-758_v1_7@3",
            "content": "Case fatality rates in immunocompromised patients with ADV pneumonia have been reported to be as high as 60% <REF-5> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_7",
            "start": 608,
            "end": 725,
            "label": {}
        },
        {
            "ix": "5-758_v1_7@4",
            "content": "Currently, there is no FDA-labeled product available for treatment of ADV infection though several agents have been administered for this indication including ribavirin <REF-6> , <REF-7> , ganciclovir <REF-8> , vidarabine <REF-9> , <REF-10> , immune globulin <REF-11> and cidofovir <REF-12> \u2013 <REF-21> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_7",
            "start": 727,
            "end": 1029,
            "label": {}
        },
        {
            "ix": "5-758_v1_8@0",
            "content": "Cidofovir (CDV), a nucleoside and phosphonate analogue is a broad-spectrum antiviral agent that inhibits viral DNA polymerase and has broad activity in vitro against multiple viruses including all serotypes of ADV <REF-22> , <REF-23> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_8",
            "start": 0,
            "end": 234,
            "label": {}
        },
        {
            "ix": "5-758_v1_8@1",
            "content": "CDV has an FDA indication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_8",
            "start": 236,
            "end": 336,
            "label": {}
        },
        {
            "ix": "5-758_v1_8@2",
            "content": "Although this drug does not have an FDA indication for treating ADV, there is evidence of in vivo efficacy of CDV against ADV <REF-12> , <REF-14> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_8",
            "start": 338,
            "end": 484,
            "label": {}
        },
        {
            "ix": "5-758_v1_8@3",
            "content": "While CDV at a standard dose of 5mg/kg has been reported as primary therapy for treatment of ADV infection in pediatric and adult hematopoietic stem cell transplantation (HSCT) patients <REF-12> , <REF-21> , concern exists regarding potential nephrotoxicity.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_8",
            "start": 486,
            "end": 743,
            "label": {}
        },
        {
            "ix": "5-758_v1_8@4",
            "content": "These associated adverse effects have limited the use of CDV for treatment of ADV infections in pediatric patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_8",
            "start": 745,
            "end": 859,
            "label": {}
        },
        {
            "ix": "5-758_v1_8@5",
            "content": "To minimize potential toxicity of CDV, modified dosing regimens such as the use of 1 mg/kg three times have been utilized <REF-14> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_8",
            "start": 861,
            "end": 992,
            "label": {}
        },
        {
            "ix": "5-758_v1_9@0",
            "content": "Limited information regarding safety and efficacy of CDV in pediatric patients prompted us to review prior published studies in the literature and conduct a retrospective review of our inpatient use of CDV at Boston Children\u2019s Hospital (BCH).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_9",
            "start": 0,
            "end": 241,
            "label": {}
        },
        {
            "ix": "5-758_v1_10@0",
            "content": "Methods",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_10",
            "start": 0,
            "end": 6,
            "label": {}
        },
        {
            "ix": "5-758_v1_11@0",
            "content": "Following Institutional Review Board (IRB) approval (IRB-P00015576), a retrospective chart review was conducted for all hospitalized patients at Boston Children\u2019s Hospital (BCH), who were prescribed CDV for adenovirus infection from January 2006 through December 2010.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_11",
            "start": 0,
            "end": 267,
            "label": {}
        },
        {
            "ix": "5-758_v1_11@1",
            "content": "The following data were collected: (1) demographic information, (2) underlying disease state, (3) type of transplant, (4) duration of cidofovir therapy, (6) serum creatinine (SCr) (baseline, peak during therapy, and level up to 2 weeks post last dose), (7) concomitant nephrotoxins prescribed (acyclovir, amikacin, cyclosporine, foscarnet, gentamicin, liposomal amphotericin B, tacrolimus, tobramycin, vancomycin, and intravenous contrast media), (8) sites of ADV detection by viral direct fluorescent antibody (DFA), nucleic acid test, and/or culture, (9) viral quantitative PCR surveillance in blood and other sites of infection (all specimens were tested at least weekly before, during and to two weeks post last dose of CDV to evaluate for changes in viral load with a minimum three serial values being obtained before, during and at end of therapy); (10) symptoms of infection, and clinical course including response to therapy, (11) concomitant reduction of immunosuppression and (12) mortality and cause(s) of mortality.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_11",
            "start": 269,
            "end": 1295,
            "label": {}
        },
        {
            "ix": "5-758_v1_11@2",
            "content": "All blood sample testing for adenovirus quantitative PCR in blood was performed at the Boston Children\u2019s Hospital Virology Laboratory using our laboratory developed test, the Argene adenovirus assay (bioMerieux, Cambridge, MA).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_11",
            "start": 1297,
            "end": 1523,
            "label": {}
        },
        {
            "ix": "5-758_v1_11@3",
            "content": "The Argene adenovirus assay contains primers and probes selective for a 138 base pair (bp) sequence in the Hexon gene of the adenovirus.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_11",
            "start": 1525,
            "end": 1660,
            "label": {}
        },
        {
            "ix": "5-758_v1_11@4",
            "content": "Using a 5\u2019 nuclease assay, viral DNA is detected using the primers and fluorescent probes from the Argene assay kit by means of real time PCR in a Cepheid SmartCycler (Cepheid, Sunnyvale, CA).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_11",
            "start": 1662,
            "end": 1853,
            "label": {}
        },
        {
            "ix": "5-758_v1_12@0",
            "content": "Definitions",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_12",
            "start": 0,
            "end": 10,
            "label": {}
        },
        {
            "ix": "5-758_v1_13@0",
            "content": "As there is no accepted definition for ADV infection or disease, we adopted definitions used in prior studies <REF-13> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_13",
            "start": 0,
            "end": 119,
            "label": {}
        },
        {
            "ix": "5-758_v1_13@1",
            "content": "Specifically, definite adenovirus disease as follows: Non-gastrointestinal locations : Symptoms and signs from the appropriate organ combined with histopathological documentation of adenovirus and/or adenovirus detection by culture, antigen test, or nucleic acid test from biopsy specimens (liver or lung), BAL fluid, or cerebrospinal fluid and without another identifiable cause; Gastrointestinal location : Symptoms together with detection of adenovirus from biopsy material by culture, antigen test, or nucleic acid test.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_13",
            "start": 121,
            "end": 644,
            "label": {}
        },
        {
            "ix": "5-758_v1_14@0",
            "content": "Probable adenovirus disease as follows: Gastrointestinal tract : Detection of adenovirus in stool by culture, antigen test, or nucleic acid test together with symptoms; Urinary tract : Symptoms of dysuria or hematuria combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause; and Respiratory tract: Symptoms and signs of pneumonia/pneumonitis combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_14",
            "start": 0,
            "end": 525,
            "label": {}
        },
        {
            "ix": "5-758_v1_15@0",
            "content": "Asymptomatic adenovirus infection as follows: any detection of adenovirus in an asymptomatic patient from stool, blood, urine, or upper airway specimens by viral culture, antigen tests, or PCR.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_15",
            "start": 0,
            "end": 192,
            "label": {}
        },
        {
            "ix": "5-758_v1_16@0",
            "content": "Adenoviremia was defined as the detection of >100 copies of ADV/mL of blood (this being the lower limit of detection of the assay).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_16",
            "start": 0,
            "end": 130,
            "label": {}
        },
        {
            "ix": "5-758_v1_16@1",
            "content": "Viral clearance was defined as an ADV viral load of <100 copies in blood by quantitative PCR at the end of therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_16",
            "start": 132,
            "end": 246,
            "label": {}
        },
        {
            "ix": "5-758_v1_16@2",
            "content": "Viral response was defined as decrease in viremia by at least one log-fold.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_16",
            "start": 248,
            "end": 322,
            "label": {}
        },
        {
            "ix": "5-758_v1_16@3",
            "content": "Clinical resolution was defined as resolution of symptoms and/or signs of infection.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_16",
            "start": 324,
            "end": 407,
            "label": {}
        },
        {
            "ix": "5-758_v1_16@4",
            "content": "Renal dysfunction was defined as a \u226550% increase in SCr from baseline during the course of CDV therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_16",
            "start": 409,
            "end": 511,
            "label": {}
        },
        {
            "ix": "5-758_v1_16@5",
            "content": "The peak SCr during therapy was used to calculate the number of patients that experienced renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_16",
            "start": 513,
            "end": 620,
            "label": {}
        },
        {
            "ix": "5-758_v1_17@0",
            "content": "Statistical analysis",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_17",
            "start": 0,
            "end": 19,
            "label": {}
        },
        {
            "ix": "5-758_v1_18@0",
            "content": "Statistical analyses employed Prism 5 for Windows Version 5.04 (GraphPad Software Inc, CA).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_18",
            "start": 0,
            "end": 90,
            "label": {}
        },
        {
            "ix": "5-758_v1_18@1",
            "content": "The Mann-Whitney test was used to assess risk of renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_18",
            "start": 92,
            "end": 158,
            "label": {}
        },
        {
            "ix": "5-758_v1_18@2",
            "content": "Trends in adenoviremia including pre-treatment viral load, changes in viral load during therapy, and post-treatment viral load were graphed.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_18",
            "start": 160,
            "end": 299,
            "label": {}
        },
        {
            "ix": "5-758_v1_19@0",
            "content": "Results",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_19",
            "start": 0,
            "end": 6,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@0",
            "content": "From January 1, 2006 to December 31, 2010, a total of 16 pediatric patients received CDV for adenovirus infection at our hospital.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 0,
            "end": 129,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@1",
            "content": "These 16 patients received 19 courses (three patients received two separate CDV courses).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 131,
            "end": 219,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@2",
            "content": "The standard CDV dose of 5mg/kg weekly was used in all courses unless there was concern for renal dysfunction at the start of therapy in which case a dosing regimen of 1mg/kg three times a week was used.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 221,
            "end": 423,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@3",
            "content": "Patient demographics, primary diagnosis, clinical symptoms and course, and sites of adenovirus detection appear in Table 1 .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 425,
            "end": 548,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@4",
            "content": "Patient age ranged from 0.75\u201320 years (mean 6.5 years).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 550,
            "end": 604,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@5",
            "content": "Seven (44%) patients were male.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 606,
            "end": 636,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@6",
            "content": "Underlying primary diagnosis included 8 (50%) HSCT (1 autologous), 4 (25%) SOT, 2 (12.5%) leukemia, and 2 (6.5%) defined as other.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 638,
            "end": 767,
            "label": {}
        },
        {
            "ix": "5-758_v1_22@7",
            "content": "Duration of CDV therapy ranged from 5\u201382 days (median 33.5 days).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_22",
            "start": 769,
            "end": 833,
            "label": {}
        },
        {
            "ix": "5-758_v1_23@0",
            "content": "Table 1.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_23",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v1_25@0",
            "content": "Of the 19 courses prescribed ( Table 1 ), two courses were prescribed in a patient with definite adenovirus disease of the gastrointestinal tract, 15 courses were prescribed in patients with probable disease and two courses were prescribed in patients with asymptomatic infection.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_25",
            "start": 0,
            "end": 279,
            "label": {}
        },
        {
            "ix": "5-758_v1_25@1",
            "content": "Sixteen courses (84%) were in patients who had a positive blood ADV PCR either in whole blood only or in combination with positive ADV PCR of sputum, stool, urine, broncho-alveolar lavage (BAL) fluid, pericardial fluid or positive sputum adenoviral DFA sample.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_25",
            "start": 281,
            "end": 540,
            "label": {}
        },
        {
            "ix": "5-758_v1_25@2",
            "content": "Respiratory symptoms were the most common presentation in 10 courses (53%) of which six courses were prescribed for patients with respiratory symptoms and radiological evidence of pneumonia.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_25",
            "start": 542,
            "end": 731,
            "label": {}
        },
        {
            "ix": "5-758_v1_25@3",
            "content": "Two courses were prescribed in patients who presented with prolonged fevers; four courses were prescribed in patients who had worsening diarrhea and colitis, two of which were biopsy proven adenovirus infection; four courses were prescribed in patients with viral sepsis with or without pneumonia; and two courses were administered in patients with severe hemorrhagic cystitis.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_25",
            "start": 733,
            "end": 1109,
            "label": {}
        },
        {
            "ix": "5-758_v1_25@4",
            "content": "Two courses were prescribed in patients with asymptomatic respiratory tract infection and asymptomatic gastrointestinal infection respectively.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_25",
            "start": 1111,
            "end": 1253,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@0",
            "content": "We further examined the 16 blood-positive courses to assess trends in ADV viral load pre-, during and post- CDV therapy ( Figure 1 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 0,
            "end": 132,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@1",
            "content": "A quantitative reduction in viral load was seen in 15 blood positive courses (94%) with viral clearance achieved in 14 (88%).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 134,
            "end": 258,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@2",
            "content": "Of note, all solid organ transplant recipients treated with CDV also had concomitant decrease in their immunosuppression.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 260,
            "end": 380,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@3",
            "content": "A single patient (Patient 6) did not demonstrate viral response to therapy and expired.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 382,
            "end": 468,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@4",
            "content": "The majority of adenovirus blood-positive CDV courses (10/16, 63%) were associated with clinical improvement with viral clearance, however this was not the case in four courses.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 470,
            "end": 646,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@5",
            "content": "Patients 7, 10, 11 and 16 expired despite demonstrating viral clearance.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 648,
            "end": 719,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@6",
            "content": "Patients 6, 7 and 16 had multiple other co-infections.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 721,
            "end": 774,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@7",
            "content": "Patients 11 and 16 developed severe hemorrhagic cystitis.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 776,
            "end": 832,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@8",
            "content": "Patient 11 experienced significant complications of hemorrhagic cystitis including urinary tract obstruction, renal failure and bladder perforation.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 834,
            "end": 981,
            "label": {}
        },
        {
            "ix": "5-758_v1_26@9",
            "content": "Patient 16 also had concomitant BK Polyoma virus detected in the urine.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_26",
            "start": 983,
            "end": 1053,
            "label": {}
        },
        {
            "ix": "5-758_v1_27@0",
            "content": "Figure 1.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_27",
            "start": 0,
            "end": 8,
            "label": {}
        },
        {
            "ix": "5-758_v1_29@0",
            "content": "Each patient\u2019s medication profile was assessed to determine the number of additional nephrotoxic agents concomitantly prescribed during CDV therapy (from Day 1 to 7 days post last CDV dose).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_29",
            "start": 0,
            "end": 189,
            "label": {}
        },
        {
            "ix": "5-758_v1_29@1",
            "content": "All 19 courses prescribed had at least one additional nephrotoxic agent prescribed during CDV therapy ( Table 2 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_29",
            "start": 191,
            "end": 304,
            "label": {}
        },
        {
            "ix": "5-758_v1_29@2",
            "content": "Four courses (21%) had only one additional nephrotoxic medication prescribed, five courses (26%) had two such medications prescribed, six courses (32%) had three prescribed, two courses (11%) had four prescribed, and two courses (11%) had five prescribed.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_29",
            "start": 306,
            "end": 560,
            "label": {}
        },
        {
            "ix": "5-758_v1_30@0",
            "content": "Table 2.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_30",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v1_32@0",
            "content": "Administration of CDV was significantly associated with occurrence of renal dysfunction when comparing the peak Cr measured during CDV therapy to the baseline serum Cr (p=0.0016).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_32",
            "start": 0,
            "end": 178,
            "label": {}
        },
        {
            "ix": "5-758_v1_32@1",
            "content": "Eleven courses (58%) were associated with development of renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_32",
            "start": 180,
            "end": 254,
            "label": {}
        },
        {
            "ix": "5-758_v1_32@2",
            "content": "Cr increased by a mean of ~50% from baseline during CDV therapy ( Figure 2 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_32",
            "start": 256,
            "end": 332,
            "label": {}
        },
        {
            "ix": "5-758_v1_32@3",
            "content": "Of the courses with elevation in serum creatinine, 64% demonstrated return to pre-treatment creatinine levels following cessation of CDV therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_32",
            "start": 334,
            "end": 478,
            "label": {}
        },
        {
            "ix": "5-758_v1_32@4",
            "content": "There was no statistically significant difference when assessing for increased risk of renal dysfunction if patients received \u2264 1 additional nephrotoxic agent or \u2265 2 additional nephrotoxic agents.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_32",
            "start": 480,
            "end": 675,
            "label": {}
        },
        {
            "ix": "5-758_v1_33@0",
            "content": "Figure 2.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_33",
            "start": 0,
            "end": 8,
            "label": {}
        },
        {
            "ix": "5-758_v1_35@0",
            "content": "Discussion",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_35",
            "start": 0,
            "end": 9,
            "label": {}
        },
        {
            "ix": "5-758_v1_36@0",
            "content": "In this retrospective review of patients treated with CDV for adenovirus infection at our hospital during a 5-year period, we assessed the safety and potential efficacy of the medication in pediatric patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_36",
            "start": 0,
            "end": 208,
            "label": {}
        },
        {
            "ix": "5-758_v1_36@1",
            "content": "Our review yielded a case series of 16 patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_36",
            "start": 210,
            "end": 257,
            "label": {}
        },
        {
            "ix": "5-758_v1_36@2",
            "content": "While the number of patients is modest, this series adds to the existing literature describing the use of CDV in pediatric recipients of HSCT, SOT and chemotherapy for oncologic diagnoses ( Table 3 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_36",
            "start": 259,
            "end": 458,
            "label": {}
        },
        {
            "ix": "5-758_v1_37@0",
            "content": "Table 3.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_37",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v1_39@0",
            "content": "Similar to other studies the majority of our patients had received a HSCT or had an oncologic diagnosis and received chemotherapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_39",
            "start": 0,
            "end": 129,
            "label": {}
        },
        {
            "ix": "5-758_v1_39@1",
            "content": "We identified eight publications describing the use of CDV for adenovirus infection in the setting of HSCT or oncologic diagnoses treated with chemotherapy ( Table 3 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_39",
            "start": 131,
            "end": 298,
            "label": {}
        },
        {
            "ix": "5-758_v1_39@2",
            "content": "Three of these studies <REF-14> , <REF-17> , <REF-27> reported viral clearance in 89\u2013100% of their patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_39",
            "start": 300,
            "end": 407,
            "label": {}
        },
        {
            "ix": "5-758_v1_39@3",
            "content": "We observed similar rates of viral clearance (88%) but this was not consistently associated with clinical improvement.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_39",
            "start": 409,
            "end": 526,
            "label": {}
        },
        {
            "ix": "5-758_v1_40@0",
            "content": "There are very few reports on the use of CDV for adenovirus infection in pediatric SOT recipients, which have largely been restricted to reports of children receiving liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_40",
            "start": 0,
            "end": 235,
            "label": {}
        },
        {
            "ix": "5-758_v1_40@1",
            "content": "We identified four publications reporting the use of CDV for adenovirus infection in pediatric SOT recipients limited to one to four per report and all of these children having received liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_40",
            "start": 237,
            "end": 491,
            "label": {}
        },
        {
            "ix": "5-758_v1_40@2",
            "content": "Doan et al. <REF-25> described children who had received lung transplants with reported viral clearance in three of their four patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_40",
            "start": 493,
            "end": 628,
            "label": {}
        },
        {
            "ix": "5-758_v1_40@3",
            "content": "Our case series contributes patients who received several types of SOT including lung, heart, combined kidney and liver, and multi-visceral transplants.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_40",
            "start": 630,
            "end": 781,
            "label": {}
        },
        {
            "ix": "5-758_v1_40@4",
            "content": "All patients with SOT in our series demonstrated viral clearance as well as resolution of symptoms, which may have reflected a combination of both the antiviral effect of CDV coupled with reduced immunosuppression.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_40",
            "start": 783,
            "end": 996,
            "label": {}
        },
        {
            "ix": "5-758_v1_41@0",
            "content": "Two-thirds of our patients experienced resolution of their symptoms and had an overall favorable clinical course with recovery.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_41",
            "start": 0,
            "end": 126,
            "label": {}
        },
        {
            "ix": "5-758_v1_41@1",
            "content": "However, one-third died all of which were stem cell transplant recipients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_41",
            "start": 128,
            "end": 201,
            "label": {}
        },
        {
            "ix": "5-758_v1_41@2",
            "content": "With the exception of one patient it is unclear whether adenovirus was the direct cause of mortality in these patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_41",
            "start": 203,
            "end": 321,
            "label": {}
        },
        {
            "ix": "5-758_v1_41@3",
            "content": "Our observations are consistent with what has been reported in the literature pertaining to outcomes in stem cell transplant recipients with adenovirus infections who have been treated with CDV <REF-9> , <REF-12> , <REF-14> , <REF-18> , <REF-23> , <REF-27> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_41",
            "start": 323,
            "end": 580,
            "label": {}
        },
        {
            "ix": "5-758_v1_41@4",
            "content": "Among SCT patients mortality remains high (10%\u201370%) even when clearance from blood is seen.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_41",
            "start": 582,
            "end": 672,
            "label": {}
        },
        {
            "ix": "5-758_v1_42@0",
            "content": "In our case series, renal dysfunction was common during CDV therapy with patients experiencing an average 50% increase of serum creatinine from their baseline.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_42",
            "start": 0,
            "end": 158,
            "label": {}
        },
        {
            "ix": "5-758_v1_42@1",
            "content": "However, renal dysfunction was transient in the majority of patients with serum creatinine returning to baseline after cessation of CDV therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_42",
            "start": 160,
            "end": 303,
            "label": {}
        },
        {
            "ix": "5-758_v1_42@2",
            "content": "While some studies have reported no toxicities related to the use of CDV <REF-14> , <REF-16> , <REF-17> , <REF-19> , <REF-25> , the transient nature of nephrotoxicity observed has been reported by other studies <REF-20> , <REF-24> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_42",
            "start": 305,
            "end": 536,
            "label": {}
        },
        {
            "ix": "5-758_v1_42@3",
            "content": "We were unable to detect any increased risk of nephrotoxicity associated with concomitant administration of additional nephrotoxic agents but this may reflect our small number of study participants.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_42",
            "start": 538,
            "end": 735,
            "label": {}
        },
        {
            "ix": "5-758_v1_43@0",
            "content": "Our study has several limitations.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_43",
            "start": 0,
            "end": 33,
            "label": {}
        },
        {
            "ix": "5-758_v1_43@1",
            "content": "Most notably, the small number of patients precluded evaluation of other factors that may impact infection resolution such as immunosuppressive regimens, and additional factors that may impact degree of renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_43",
            "start": 35,
            "end": 255,
            "label": {}
        },
        {
            "ix": "5-758_v1_43@2",
            "content": "Nevertheless, our study adds to the limited reported literature of pediatric ADV patients treated with CDV.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_43",
            "start": 257,
            "end": 363,
            "label": {}
        },
        {
            "ix": "5-758_v1_44@0",
            "content": "Data availability",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_44",
            "start": 0,
            "end": 16,
            "label": {}
        },
        {
            "ix": "5-758_v1_45@0",
            "content": "The data referenced by this article are under copyright with the following copyright statement: Copyright: \u00ef\u00bf\u00bd 2016 Ganapathi L et al.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_45",
            "start": 0,
            "end": 133,
            "label": {}
        },
        {
            "ix": "5-758_v1_46@0",
            "content": "Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_46",
            "start": 0,
            "end": 159,
            "label": {}
        },
        {
            "ix": "5-758_v1_47@0",
            "content": "F1000Research : Dataset 1.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_47",
            "start": 0,
            "end": 25,
            "label": {}
        },
        {
            "ix": "5-758_v1_47@1",
            "content": "Raw data for Figure 1 , 10.5256/f1000research.8374.d117321 <REF-28>",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_47",
            "start": 27,
            "end": 93,
            "label": {}
        },
        {
            "ix": "5-758_v1_48@0",
            "content": "F1000Research : Dataset 2.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_48",
            "start": 0,
            "end": 25,
            "label": {}
        },
        {
            "ix": "5-758_v1_48@1",
            "content": "Raw data for Figure 2 , 10.5256/f1000research.8374.d117322 <REF-29>",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_48",
            "start": 27,
            "end": 93,
            "label": {}
        },
        {
            "ix": "5-758_v1_49@0",
            "content": "<REF-1> Ison MG : Adenovirus infections in transplant recipients. Clin Infect Dis. 2006 ; 43 ( 3 ): 331 \u2013 339 . 16804849 10.1086/505498",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_49",
            "start": 0,
            "end": 134,
            "label": {}
        },
        {
            "ix": "5-758_v1_50@0",
            "content": "<REF-2> Carrigan DR : Adenovirus infections in immunocompromised patients. Am J Med. 1997 ; 102 ( 3A ): 71 \u2013 74 . 10868146",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_50",
            "start": 0,
            "end": 121,
            "label": {}
        },
        {
            "ix": "5-758_v1_51@0",
            "content": "<REF-4> Hale GA Heslop HE Krance RA : Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 ; 23 ( 3 ): 277 \u2013 282 . 10084260",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_51",
            "start": 0,
            "end": 164,
            "label": {}
        },
        {
            "ix": "5-758_v1_52@0",
            "content": "<REF-5> Hierholzer JC : Adenoviruses in the immunocompromised host. Clin Microbiol Rev. 1992 ; 5 ( 3 ): 262 \u2013 274 . 1323383 358244",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_52",
            "start": 0,
            "end": 129,
            "label": {}
        },
        {
            "ix": "5-758_v1_53@0",
            "content": "<REF-6> Gavin PJ Katz BZ : Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics. 2002 ; 110 ( 1 Pt 1 ): e9 . 12093990",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_53",
            "start": 0,
            "end": 167,
            "label": {}
        },
        {
            "ix": "5-758_v1_54@0",
            "content": "<REF-7> McCarthy AJ Bergin M De Silva LM : Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J. 1995 ; 14 ( 11 ): 1003 \u2013 1004 . 8584339 10.1097/00006454-199511000-00017",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_54",
            "start": 0,
            "end": 205,
            "label": {}
        },
        {
            "ix": "5-758_v1_55@0",
            "content": "<REF-8> Chen FE Liang RH Lo JY : Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 1997 ; 20 ( 11 ): 997 \u2013 999 . 9422482 10.1038/sj.bmt.1700997",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_55",
            "start": 0,
            "end": 191,
            "label": {}
        },
        {
            "ix": "5-758_v1_56@0",
            "content": "<REF-9> Kawakami M Ueda S Maeda T : Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997 ; 20 ( 6 ): 485 \u2013 490 . 9313882 10.1038/sj.bmt.1700923",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_56",
            "start": 0,
            "end": 213,
            "label": {}
        },
        {
            "ix": "5-758_v1_57@0",
            "content": "<REF-10> Kitabayashi A Hirokawa M Kuroki J : Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 ; 14 ( 5 ): 853 \u2013 854 . 7889020",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_57",
            "start": 0,
            "end": 241,
            "label": {}
        },
        {
            "ix": "5-758_v1_58@0",
            "content": "<REF-11> Saquib R Melton LB Chandrakantan A : Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis. 2010 ; 12 ( 1 ): 77 \u2013 83 . 19761559 10.1111/j.1399-3062.2009.00452.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_58",
            "start": 0,
            "end": 253,
            "label": {}
        },
        {
            "ix": "5-758_v1_59@0",
            "content": "<REF-12> Muller WJ Levin MJ Shin YK : Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 2005 ; 41 ( 12 ): 1812 \u2013 1816 . 16288409 10.1086/498151",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_59",
            "start": 0,
            "end": 253,
            "label": {}
        },
        {
            "ix": "5-758_v1_60@0",
            "content": "<REF-13> Ljungman P Ribaud P Eyrich M : Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2003 ; 31 ( 6 ): 481 \u2013 486 . 12665844 10.1038/sj.bmt.1703798",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_60",
            "start": 0,
            "end": 327,
            "label": {}
        },
        {
            "ix": "5-758_v1_61@0",
            "content": "<REF-14> Hoffman JA Shah AJ Ross LA : Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001 ; 7 ( 7 ): 388 \u2013 394 . 11529489 10.1053/bbmt.2001.v7.pm11529489",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_61",
            "start": 0,
            "end": 248,
            "label": {}
        },
        {
            "ix": "5-758_v1_62@0",
            "content": "<REF-16> Engelmann G Heim A Greil J : Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr Transplant. 2009 ; 13 ( 4 ): 421 \u2013 428 . 18783361 10.1111/j.1399-3046.2008.01014.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_62",
            "start": 0,
            "end": 218,
            "label": {}
        },
        {
            "ix": "5-758_v1_63@0",
            "content": "<REF-17> Yusuf U Hale GA Carr J : Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006 ; 81 ( 10 ): 1398 \u2013 1404 . 16732176 10.1097/01.tp.0000209195.95115.8e",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_63",
            "start": 0,
            "end": 234,
            "label": {}
        },
        {
            "ix": "5-758_v1_64@0",
            "content": "<REF-18> Legrand F Berrebi D Houhou N : Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 2001 ; 27 ( 6 ): 621 \u2013 626 . 11319592",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_64",
            "start": 0,
            "end": 216,
            "label": {}
        },
        {
            "ix": "5-758_v1_65@0",
            "content": "<REF-19> Anderson EJ Guzman-Cottrill JA Kletzel M : High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant. 2008 ; 12 ( 2 ): 219 \u2013 227 . 18307672 10.1111/j.1399-3046.2007.00851.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_65",
            "start": 0,
            "end": 278,
            "label": {}
        },
        {
            "ix": "5-758_v1_66@0",
            "content": "<REF-20> Wallot MA Dohna-Schwake C Auth M : Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide. Pediatr Transplant. 2006 ; 10 ( 1 ): 121 \u2013 127 . 16499602 10.1111/j.1399-3046.2005.00411.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_66",
            "start": 0,
            "end": 292,
            "label": {}
        },
        {
            "ix": "5-758_v1_67@0",
            "content": "<REF-21> Ribaud P Scieux C Freymuth F : Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis. 1999 ; 28 ( 3 ): 690 \u2013 691 . 10194105 10.1086/517222",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_67",
            "start": 0,
            "end": 226,
            "label": {}
        },
        {
            "ix": "5-758_v1_68@0",
            "content": "<REF-22> Naesens L Lenaerts L Andrei G : Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother. 2005 ; 49 ( 3 ): 1010 \u2013 1016 . 15728896 10.1128/AAC.49.3.1010-1016.2005 549266",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_68",
            "start": 0,
            "end": 232,
            "label": {}
        },
        {
            "ix": "5-758_v1_69@0",
            "content": "<REF-23> Morfin F Dupuis-Girod S Mundweiler S : In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther. 2005 ; 10 ( 2 ): 225 \u2013 229 . 15865216",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_69",
            "start": 0,
            "end": 177,
            "label": {}
        },
        {
            "ix": "5-758_v1_70@0",
            "content": "<REF-24> Carter BA Karpen SJ Quiros-Tejeira RE : Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 ; 74 ( 7 ): 1050 \u2013 1052 . 12394854",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_70",
            "start": 0,
            "end": 205,
            "label": {}
        },
        {
            "ix": "5-758_v1_71@0",
            "content": "<REF-25> Doan ML Mallory GB Kaplan SL : Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant. 2007 ; 26 ( 9 ): 883 \u2013 889 . 17845926 10.1016/j.healun.2007.06.009",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_71",
            "start": 0,
            "end": 220,
            "label": {}
        },
        {
            "ix": "5-758_v1_72@0",
            "content": "<REF-27> Williams KM Agwu AL Dabb AA : A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection. J Pediatr Hematol Oncol. 2009 ; 31 ( 11 ): 825 \u2013 831 . 19801951 10.1097/MPH.0b013e3181b7873e 4251427",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_72",
            "start": 0,
            "end": 293,
            "label": {}
        },
        {
            "ix": "5-758_v1_73@0",
            "content": "<REF-28> Ganapathi L Arnold A Jones S : Dataset 1 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_73",
            "start": 0,
            "end": 152,
            "label": {}
        },
        {
            "ix": "5-758_v1_74@0",
            "content": "<REF-29> Ganapathi L Arnold A Jones S : Dataset 2 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v1_74",
            "start": 0,
            "end": 152,
            "label": {}
        }
    ],
    "edges": [
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_1",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_1",
            "tgt_ix": "5-758_v1_2",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_1",
            "tgt_ix": "5-758_v1_3",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_1",
            "tgt_ix": "5-758_v1_4",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_1",
            "tgt_ix": "5-758_v1_5",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_6",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_6",
            "tgt_ix": "5-758_v1_7",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_6",
            "tgt_ix": "5-758_v1_8",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_6",
            "tgt_ix": "5-758_v1_9",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_10",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_10",
            "tgt_ix": "5-758_v1_11",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_10",
            "tgt_ix": "5-758_v1_12",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_12",
            "tgt_ix": "5-758_v1_13",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_12",
            "tgt_ix": "5-758_v1_14",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_12",
            "tgt_ix": "5-758_v1_15",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_12",
            "tgt_ix": "5-758_v1_16",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_10",
            "tgt_ix": "5-758_v1_17",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_17",
            "tgt_ix": "5-758_v1_18",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_19",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_20",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_21",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_22",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_23",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_23",
            "tgt_ix": "5-758_v1_24",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_25",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_26",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_27",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_27",
            "tgt_ix": "5-758_v1_28",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_29",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_30",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_30",
            "tgt_ix": "5-758_v1_31",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_32",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_33",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_33",
            "tgt_ix": "5-758_v1_34",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_35",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_36",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_37",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_37",
            "tgt_ix": "5-758_v1_38",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_39",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_40",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_41",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_42",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_43",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_44",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_44",
            "tgt_ix": "5-758_v1_45",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_44",
            "tgt_ix": "5-758_v1_46",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_44",
            "tgt_ix": "5-758_v1_47",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_44",
            "tgt_ix": "5-758_v1_48",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_1",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_1",
            "tgt_ix": "5-758_v1_2",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_2",
            "tgt_ix": "5-758_v1_3",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_3",
            "tgt_ix": "5-758_v1_4",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_4",
            "tgt_ix": "5-758_v1_5",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_5",
            "tgt_ix": "5-758_v1_6",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_6",
            "tgt_ix": "5-758_v1_7",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_8",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_9",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_9",
            "tgt_ix": "5-758_v1_10",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_10",
            "tgt_ix": "5-758_v1_11",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_11",
            "tgt_ix": "5-758_v1_12",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_12",
            "tgt_ix": "5-758_v1_13",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_13",
            "tgt_ix": "5-758_v1_14",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_14",
            "tgt_ix": "5-758_v1_15",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_15",
            "tgt_ix": "5-758_v1_16",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_16",
            "tgt_ix": "5-758_v1_17",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_17",
            "tgt_ix": "5-758_v1_18",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_18",
            "tgt_ix": "5-758_v1_19",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_20",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_20",
            "tgt_ix": "5-758_v1_21",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_21",
            "tgt_ix": "5-758_v1_22",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_23",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_23",
            "tgt_ix": "5-758_v1_24",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_24",
            "tgt_ix": "5-758_v1_25",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_25",
            "tgt_ix": "5-758_v1_26",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_27",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_27",
            "tgt_ix": "5-758_v1_28",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_28",
            "tgt_ix": "5-758_v1_29",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_29",
            "tgt_ix": "5-758_v1_30",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_30",
            "tgt_ix": "5-758_v1_31",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_31",
            "tgt_ix": "5-758_v1_32",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_32",
            "tgt_ix": "5-758_v1_33",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_33",
            "tgt_ix": "5-758_v1_34",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_34",
            "tgt_ix": "5-758_v1_35",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_36",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_36",
            "tgt_ix": "5-758_v1_37",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_37",
            "tgt_ix": "5-758_v1_38",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_38",
            "tgt_ix": "5-758_v1_39",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_39",
            "tgt_ix": "5-758_v1_40",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_41",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_41",
            "tgt_ix": "5-758_v1_42",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_42",
            "tgt_ix": "5-758_v1_43",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_43",
            "tgt_ix": "5-758_v1_44",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_44",
            "tgt_ix": "5-758_v1_45",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_45",
            "tgt_ix": "5-758_v1_46",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_46",
            "tgt_ix": "5-758_v1_47",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_47",
            "tgt_ix": "5-758_v1_48",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_49",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_50",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_51",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_52",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_53",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_54",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_55",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_56",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_57",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_58",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_59",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_13",
            "tgt_ix": "5-758_v1_60",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_61",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_62",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_39",
            "tgt_ix": "5-758_v1_63",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_41",
            "tgt_ix": "5-758_v1_64",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_42",
            "tgt_ix": "5-758_v1_65",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_66",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_67",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_68",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_69",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_70",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_71",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_39",
            "tgt_ix": "5-758_v1_72",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_47",
            "tgt_ix": "5-758_v1_73",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_48",
            "tgt_ix": "5-758_v1_74",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_24",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_28",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_29",
            "tgt_ix": "5-758_v1_31",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_32",
            "tgt_ix": "5-758_v1_34",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_36",
            "tgt_ix": "5-758_v1_38",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v1_0",
            "tgt_ix": "5-758_v1_0@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_1",
            "tgt_ix": "5-758_v1_1@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_2",
            "tgt_ix": "5-758_v1_2@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_2",
            "tgt_ix": "5-758_v1_2@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_3",
            "tgt_ix": "5-758_v1_3@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_3",
            "tgt_ix": "5-758_v1_3@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_4",
            "tgt_ix": "5-758_v1_4@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_4",
            "tgt_ix": "5-758_v1_4@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_4",
            "tgt_ix": "5-758_v1_4@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_4",
            "tgt_ix": "5-758_v1_4@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_4",
            "tgt_ix": "5-758_v1_4@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_5",
            "tgt_ix": "5-758_v1_5@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_5",
            "tgt_ix": "5-758_v1_5@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_6",
            "tgt_ix": "5-758_v1_6@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_7@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_7@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_7@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_7@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_7",
            "tgt_ix": "5-758_v1_7@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_8@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_8@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_8@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_8@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_8@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_8",
            "tgt_ix": "5-758_v1_8@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_9",
            "tgt_ix": "5-758_v1_9@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_10",
            "tgt_ix": "5-758_v1_10@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_11",
            "tgt_ix": "5-758_v1_11@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_11",
            "tgt_ix": "5-758_v1_11@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_11",
            "tgt_ix": "5-758_v1_11@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_11",
            "tgt_ix": "5-758_v1_11@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_11",
            "tgt_ix": "5-758_v1_11@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_12",
            "tgt_ix": "5-758_v1_12@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_13",
            "tgt_ix": "5-758_v1_13@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_13",
            "tgt_ix": "5-758_v1_13@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_14",
            "tgt_ix": "5-758_v1_14@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_15",
            "tgt_ix": "5-758_v1_15@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_16",
            "tgt_ix": "5-758_v1_16@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_16",
            "tgt_ix": "5-758_v1_16@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_16",
            "tgt_ix": "5-758_v1_16@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_16",
            "tgt_ix": "5-758_v1_16@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_16",
            "tgt_ix": "5-758_v1_16@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_16",
            "tgt_ix": "5-758_v1_16@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_17",
            "tgt_ix": "5-758_v1_17@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_18",
            "tgt_ix": "5-758_v1_18@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_18",
            "tgt_ix": "5-758_v1_18@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_18",
            "tgt_ix": "5-758_v1_18@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_19",
            "tgt_ix": "5-758_v1_19@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_22",
            "tgt_ix": "5-758_v1_22@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_23",
            "tgt_ix": "5-758_v1_23@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_25",
            "tgt_ix": "5-758_v1_25@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_25",
            "tgt_ix": "5-758_v1_25@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_25",
            "tgt_ix": "5-758_v1_25@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_25",
            "tgt_ix": "5-758_v1_25@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_25",
            "tgt_ix": "5-758_v1_25@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_26",
            "tgt_ix": "5-758_v1_26@9",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_27",
            "tgt_ix": "5-758_v1_27@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_29",
            "tgt_ix": "5-758_v1_29@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_29",
            "tgt_ix": "5-758_v1_29@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_29",
            "tgt_ix": "5-758_v1_29@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_30",
            "tgt_ix": "5-758_v1_30@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_32",
            "tgt_ix": "5-758_v1_32@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_32",
            "tgt_ix": "5-758_v1_32@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_32",
            "tgt_ix": "5-758_v1_32@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_32",
            "tgt_ix": "5-758_v1_32@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_32",
            "tgt_ix": "5-758_v1_32@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_33",
            "tgt_ix": "5-758_v1_33@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_35",
            "tgt_ix": "5-758_v1_35@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_36",
            "tgt_ix": "5-758_v1_36@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_36",
            "tgt_ix": "5-758_v1_36@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_36",
            "tgt_ix": "5-758_v1_36@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_37",
            "tgt_ix": "5-758_v1_37@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_39",
            "tgt_ix": "5-758_v1_39@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_39",
            "tgt_ix": "5-758_v1_39@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_39",
            "tgt_ix": "5-758_v1_39@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_39",
            "tgt_ix": "5-758_v1_39@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_40@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_40@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_40@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_40@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_40",
            "tgt_ix": "5-758_v1_40@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_41",
            "tgt_ix": "5-758_v1_41@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_41",
            "tgt_ix": "5-758_v1_41@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_41",
            "tgt_ix": "5-758_v1_41@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_41",
            "tgt_ix": "5-758_v1_41@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_41",
            "tgt_ix": "5-758_v1_41@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_42",
            "tgt_ix": "5-758_v1_42@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_42",
            "tgt_ix": "5-758_v1_42@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_42",
            "tgt_ix": "5-758_v1_42@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_42",
            "tgt_ix": "5-758_v1_42@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_43",
            "tgt_ix": "5-758_v1_43@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_43",
            "tgt_ix": "5-758_v1_43@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_43",
            "tgt_ix": "5-758_v1_43@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_44",
            "tgt_ix": "5-758_v1_44@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_45",
            "tgt_ix": "5-758_v1_45@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_46",
            "tgt_ix": "5-758_v1_46@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_47",
            "tgt_ix": "5-758_v1_47@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_47",
            "tgt_ix": "5-758_v1_47@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_48",
            "tgt_ix": "5-758_v1_48@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_48",
            "tgt_ix": "5-758_v1_48@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_49",
            "tgt_ix": "5-758_v1_49@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_50",
            "tgt_ix": "5-758_v1_50@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_51",
            "tgt_ix": "5-758_v1_51@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_52",
            "tgt_ix": "5-758_v1_52@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_53",
            "tgt_ix": "5-758_v1_53@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_54",
            "tgt_ix": "5-758_v1_54@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_55",
            "tgt_ix": "5-758_v1_55@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_56",
            "tgt_ix": "5-758_v1_56@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_57",
            "tgt_ix": "5-758_v1_57@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_58",
            "tgt_ix": "5-758_v1_58@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_59",
            "tgt_ix": "5-758_v1_59@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_60",
            "tgt_ix": "5-758_v1_60@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_61",
            "tgt_ix": "5-758_v1_61@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_62",
            "tgt_ix": "5-758_v1_62@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_63",
            "tgt_ix": "5-758_v1_63@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_64",
            "tgt_ix": "5-758_v1_64@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_65",
            "tgt_ix": "5-758_v1_65@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_66",
            "tgt_ix": "5-758_v1_66@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_67",
            "tgt_ix": "5-758_v1_67@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_68",
            "tgt_ix": "5-758_v1_68@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_69",
            "tgt_ix": "5-758_v1_69@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_70",
            "tgt_ix": "5-758_v1_70@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_71",
            "tgt_ix": "5-758_v1_71@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_72",
            "tgt_ix": "5-758_v1_72@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_73",
            "tgt_ix": "5-758_v1_73@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v1_74",
            "tgt_ix": "5-758_v1_74@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        }
    ],
    "prefix": "5-758_v1",
    "meta": {
        "parser": "F1000XMLParser",
        "intertext-graph": "N/A",
        "doi": "10.12688/f1000research.8374.1",
        "atype": "research-note",
        "license": "http://creativecommons.org/licenses/by/4.0/",
        "title": "Use of cidofovir in pediatric patients with adenovirus infection",
        "abstract": "Background : Adenoviruses contribute to morbidity and mortality among immunocompromised pediatric patients including stem cell and solid organ transplant recipients. Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompromised patients despite concern of potential nephrotoxicity. Methods : We conducted a retrospective 5-year review at Boston Children\u2019s Hospital of 16 patients (mean age = 6.5 years) receiving 19 courses of CDV. During therapy all pertinent data elements were reviewed to characterize potential response to therapy and incidence of renal dysfunction. Results: Of the 19 CDV courses prescribed, 16 courses (84%) were in patients who had a positive blood ADV Polymerase chain reaction (PCR) alone or in combination with positive ADV PCR/ Direct Immunofluorescence Assay (DFA) at another site. Respiratory symptoms with or without pneumonia were the most common presentation (10/19, 53%). In the majority of blood positive courses (10/16, 63%), viral clearance was also accompanied by clinical response. This was not the case in four courses where patients expired despite viral clearance, including one in which death was directly attributable to adenovirus. There was reversible renal dysfunction observed during the use of CDV. Conclusions: CDV appeared safe and reasonably tolerated for treatment of ADV in this pediatric population and was associated with viral response and clinical improvement in the majority of patients but reversible renal dysfunction was a side effect. Further studies of the efficacy of CDV for immunocompromised children with ADV infection are warranted.",
        "contributors": [
            {
                "surname": "Ganapathi",
                "given-names": "Lakshmi"
            },
            {
                "surname": "Arnold",
                "given-names": "Alana"
            },
            {
                "surname": "Jones",
                "given-names": "Sarah"
            },
            {
                "surname": "Patterson",
                "given-names": "Al"
            },
            {
                "surname": "Graham",
                "given-names": "Dionne"
            },
            {
                "surname": "Harper",
                "given-names": "Marvin"
            },
            {
                "surname": "Levy",
                "given-names": "Ofer"
            }
        ],
        "url": "https://f1000research.com/articles/5-758/v1/",
        "doc_id": "5-758",
        "version": 1,
        "ix_counter": 291,
        "sentence_split_type": "HybridSplitterLessAndLong",
        "sentence_split_model": "HybridSplitterLessAndLong_SciSpacy+Spacy"
    }
}